Sangamo Therapeutics, Inc. Board of Directors

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Dr. Nathalie Dubois-Stringfellow Ph.D.

Dr. Nathalie Dubois-Stringfellow Ph.D.

Senior VP & Chief Development Officer

Mr. Gregory Davis Ph.D.

Mr. Gregory Davis Ph.D.

Head of Research & Technology

Mr. David Ojala

Mr. David Ojala

Scientist II - Discovery & Translational Research

Ms. Stephanie J. Seiler CLP

Ms. Stephanie J. Seiler CLP

Head of Business Development & Alliance Management

Ms. Aron Feingold

Ms. Aron Feingold

Head of Corporate Communications & Investor Relations Officer

Mr. Phillip Ramsey

Mr. Phillip Ramsey

Head of Technical Operations

Mr. Scott B. Willoughby

Mr. Scott B. Willoughby

Senior VP, General Counsel & Corporate Secretary

Ms. Louise Wilkie

Ms. Louise Wilkie

Vice President of Investor Relations & Corporate Communications

Ms. Prathyusha Duraibabu CPA, M.B.A.

Ms. Prathyusha Duraibabu CPA, M.B.A.

Senior VP, CFO & Principal Accounting Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.